Fingerprint
Dive into the research topics of 'Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically